FDA clears Pfizer to restart Duchenne gene therapy trial, with new safeguards
Bio Pharma Dive
APRIL 28, 2022
The regulator has asked Pfizer to closely monitor patients in a hospital setting for a week as part of a deal to end a study suspension that's lasted more than four months.
Let's personalize your content